Trials / Unknown
UnknownNCT06311903
Norepinephrine in Preperiod of Hypotensive Resuscitation in Hemorrhagic Shock
Is Low Dose Norepinephrine Effective in Preperiod of Hypotensive Resuscitation in Hemorrhagic Shock?
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this work was to investigate the effects of low dose of norepinephrine in preperiod of hypotensive resuscitation in hemorrhagic shock.
Detailed description
Hemorrhagic shock is one of the leading causes of death following trauma. New fluid resuscitation concepts, including hypotensive, hypothermic, and delayed resuscitation for uncontrolled hemorrhagic shock, have been put forward and obtained a good effect both in clinical and laboratory parameters. The 2019 European guideline on the management of major bleeding and coagulopathy following trauma recommends the use of norepinephrine (NE) for maintaining target arterial blood pressure in patients with life-threatening hypotension. NE has potent α-adrenergic receptor activation activity, which can stimulate α-1 adrenergic receptors on peripheral vascular smooth muscles. High-dose NE may result in excessive arteriolar vasoconstriction which subsequently leads to the disorder of microcirculation and tissue hypoxia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low dose of Norepinephrine (NE) | Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure \>70 mmHg)\] followed by low dose of NE (0.05-0.2 μg/kg/min). |
| DRUG | High dose of Norepinephrine (NE) | Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min). |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
- First posted
- 2024-03-15
- Last updated
- 2024-03-15
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06311903. Inclusion in this directory is not an endorsement.